midodrine has been researched along with Idiopathic Parkinson Disease in 9 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and parkinsonism due either to Parkinson's disease or multiple system atrophy." | 9.09 | Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. ( Brady, CM; Fowler, CJ; Hussain, IF; Mathias, CJ; Swinn, MJ, 2001) |
| "To assess the efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and parkinsonism due either to Parkinson's disease or multiple system atrophy." | 5.09 | Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. ( Brady, CM; Fowler, CJ; Hussain, IF; Mathias, CJ; Swinn, MJ, 2001) |
| "Neurogenic orthostatic hypotension (nOH) is among the most debilitating nonmotor features of patients with Parkinson's disease (PD) and other synucleinopathies." | 2.66 | Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges. ( Kaufmann, H; Palma, JA, 2020) |
| "Parkinson's disease is a cause of primary autonomic failure with involvement of the peripheral nervous system." | 2.42 | [Blood pressure disorders during idiopathic Parkinson's disease]. ( Senard, JM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Palma, JA | 1 |
| Kaufmann, H | 1 |
| Goodman, BP | 2 |
| Claassen, D | 3 |
| Mehdirad, A | 1 |
| Kremens, D | 1 |
| Lew, M | 1 |
| Vernino, S | 1 |
| Asahina, M | 1 |
| Akaogi, Y | 1 |
| Yamanaka, Y | 1 |
| Koyama, Y | 1 |
| Hattori, T | 1 |
| Senard, JM | 1 |
| Jörg, J | 1 |
| Couban, S | 1 |
| Hussain, IF | 1 |
| Brady, CM | 1 |
| Swinn, MJ | 1 |
| Mathias, CJ | 1 |
| Fowler, CJ | 1 |
2 reviews available for midodrine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.
Topics: Adrenergic alpha-1 Receptor Agonists; Antiparkinson Agents; Clinical Trials as Topic; Droxidopa; Hum | 2020 |
[Blood pressure disorders during idiopathic Parkinson's disease].
Topics: Adrenergic alpha-Agonists; Aged; Aging; Fludrocortisone; Humans; Hypotension, Orthostatic; Midodrine | 2003 |
1 trial available for midodrine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension.
Topics: Aged; Blood Pressure; Cross-Over Studies; Diastole; Double-Blind Method; Ephedrine; Erectile Dysfunc | 2001 |
6 other studies available for midodrine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Droxidopa; Female; Humans; Hypotension, Orthostatic; Midodrine; Parkinso | 2017 |
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
Topics: Antiparkinson Agents; Droxidopa; Drug Therapy, Combination; Female; Fludrocortisone; Humans; Hypoten | 2017 |
Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
Topics: Aged; Antiparkinson Agents; Diabetes Mellitus, Type 2; Droxidopa; Female; Humans; Hypotension, Ortho | 2017 |
Differences in skin sympathetic involvements between two chronic autonomic disorders: multiple system atrophy and pure autonomic failure.
Topics: Aged; Autonomic Nervous System Diseases; Blood Flow Velocity; Blood Pressure; Female; Fludrocortison | 2009 |
[Therapeutic concept in Parkinson disease].
Topics: Adrenergic beta-Antagonists; Amantadine; Antidepressive Agents, Tricyclic; Benzodiazepines; Bromocri | 1983 |
Confusion of drug names signalled.
Topics: Aged; Aged, 80 and over; Amantadine; Humans; Male; Medication Errors; Midodrine; Parkinson Disease | 1995 |